M.D. Anderson Cancer Center
CompanyUnited States
M.D. Anderson Cancer Center develops one asset, in phase 3 (anamorelin hydrochloride in non-small cell lung cancer). Mostly small molecule acting on GHSR; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 3
- 1,530
- Trials
- 6
- Signals
Pipeline
1Activates ghrelin receptors to stimulate appetite and growth hormone release.
Phase 3, Small molecule, GHSR, non-small cell lung cancer, cachexia
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms2
- Trials1,596
- Deals1
- Signals12
- Integrity notices10
- Similar companies6